Wednesday, November 11, 2026
Barclays kept its Overweight rating on Ligand Pharmaceuticals (LGND) and raised its price target to $350 from $345.
Thursday, November 5, 2026
Citi kept its Buy rating on Ligand Pharmaceuticals (LGND) and raised its price target to $402 from $397.
Friday, October 30, 2026
RBC Capital kept its Outperform rating on Ligand Pharmaceuticals (LGND) and raised its price target to $357 from $345.
Friday, September 25, 2026
Barclays started coverage of Ligand Pharmaceuticals (LGND) with an Overweight rating and a price target of $345.
Thursday, September 24, 2026
HC Wainwright & Co. kept its Buy rating on Ligand Pharmaceuticals (LGND).
Wednesday, September 23, 2026
Citi kept its Buy rating on Ligand Pharmaceuticals (LGND) and raised its price target to $397 from $387.
Friday, August 14, 2026
Leerink Partners started coverage of Ligand Pharmaceuticals (LGND) with an Outperform rating and a price target of $330.
Frequently asked questions
What is the latest news on LGND?
Nov 11, 2026: Barclays kept its Overweight rating on Ligand Pharmaceuticals (LGND) and raised its price target to $350 from $345. (Barclays) · Nov 5, 2026: Citi kept its Buy rating on Ligand Pharmaceuticals (LGND) and raised its price target to $402 from $397. (Citi) · Oct 30, 2026: RBC Capital kept its Outperform rating on Ligand Pharmaceuticals (LGND) and raised its price target to $357 from $345. (RBC Capital)
What are analysts saying about LGND?
Nov 11, 2026: Barclays kept its Overweight rating on Ligand Pharmaceuticals (LGND) and raised its price target to $350 from $345. · Nov 5, 2026: Citi kept its Buy rating on Ligand Pharmaceuticals (LGND) and raised its price target to $402 from $397. · Oct 30, 2026: RBC Capital kept its Outperform rating on Ligand Pharmaceuticals (LGND) and raised its price target to $357 from $345.
Get LGND news as it happens
Every headline, SEC filing and analyst action for LGND on your live chart, with important news marked and alerts when it matters.
Try SEPT Free